All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer

April 16th 2024

Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.

Olutasidenib Elicits Durable Remissions With/Without Azacitidine in IDH1-Mutant MDS

April 16th 2024

Olutasidenib alone or administered with azacitidine was safe and clinically effective in patients with IDH1-mutated myelodysplastic syndrome.

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

April 15th 2024

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

April 15th 2024

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

April 15th 2024

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

BTK Inhibitor Selection for CLL/SLL Is Evolving in Community Settings

April 15th 2024

A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.

MRD-Negative CR Separates Ponatinib From the Rest in Newly Diagnosed, Ph+ ALL

April 15th 2024

Ibrahim Aldoss, MD, discusses the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.

Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL

April 15th 2024

Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.

Glofitamab Plus Chemotherapy Meets OS End Point in R/R DLBCL

April 15th 2024

Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Dana-Farber Cancer Institute Earns Fifth Consecutive Magnet® Designation Recognizing Excellence in Nursing Practice and Patient Care

April 15th 2024

The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.

Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups

April 15th 2024

Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.

First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer

April 14th 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL

April 12th 2024

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma

April 12th 2024

The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.

Increasingly Targeted ADCs Drive NSCLC Treatment Innovations

April 12th 2024

Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.

Examining the Evolution of Treatment With Targeted Agents in Metastatic Breast Cancer

April 12th 2024

Anne Favret, MD discusses the evolution of treatment with endocrine-based combination therapies in HR-positive/HER2-negative metastatic breast cancer.

Fox Chase Cancer Center and Temple University Hospital Recertified Under ASCO’s Quality Oncology Practice Initiative

April 12th 2024

Fox Chase Cancer Center has been recognized by the QOPI Certification Program LLC as successfully completing a 3-year recertification for outpatient hematology-oncology practices that meet nationally recognized standards for quality cancer care.

Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC

April 12th 2024

Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.